| Literature DB >> 36033924 |
Anselm Poda1, Raymond Klevor1,2, Aouatif Salym1, Imad Sarih1, Sami Salhi1, Louhab Nissrine1,2, Najib Kissani1,2.
Abstract
Background: Peripheral neuropathies constitute a common complaint in general and neurology practice, and are a source of handicap to patients. Epidemiological data in the Middle East and North Africa region as well as in the African continent are sparse. Nevertheless, regional etiological profiles are crucial in navigating the diagnostic maze of neuropathies. This study outlines the etiological profile of peripheral neuropathies in an academic hospital in southern Morocco.Entities:
Keywords: Acute polyradiculoneuropathy; Alcohol; Diabetes; Etiology; Morocco; Peripheral neuropathy
Year: 2022 PMID: 36033924 PMCID: PMC9391624 DOI: 10.1186/s41983-022-00531-4
Source DB: PubMed Journal: Egypt J Neurol Psychiatr Neurosurg ISSN: 1110-1083
Criteria for making etiological diagnosis of peripheral neuropathies [7]
| Diagnosis | Definition of neuropathy |
|---|---|
| Diabetes | Patient with diabetes mellitus presenting peripheral neuropathy in whom workup finds no alternative cause |
| Acute polyradiculoneuropathy | Acute (< 4 weeks) of ascending bilateral symmetric peripheral neuropathy. Deep tendon reflexes are abolished or diminished; with prolonged distal latencies and F waves, and reduced motor conduction velocities |
| Motor neuron disease | Association of upper and lower motor neuron impairment in diffuse distribution with fasciculations; neuronopathy on electrophysiological evaluation; absence of compressive or other secondary cause |
| Immunologic | Peripheral neuropathy in the context of (either inaugurating or associated with) an autoimmune condition such as Lupus, sarcoidosis, Sjogren’s… |
| Idiopathic | Peripheral neuropathy with negative paraclinical findings despite extensive workup |
| Medication-induced | Peripheral neuropathy in the context of exposure to a medication known to cause neuropathy. Neuropathy is either inaugural or an underlying neuropathy is worsened when medication is started. Typically patients are undergoing anti-cancer medications such vincristine, cisplatine, nucleosidic analogue anti-retroviral agents, dapsone and phenytoin. Etiologic workup is unremarkable, and patients tend to stabilize or recover upon medication retraction |
| Infective | Neuropathy in the context of infection diagnosed on cerebrospinal fluid (CSF) analysis. CSF evaluation includes cell count, protein, glucose levels, soluble antigens, culture, and polymerase chain reaction (PCR) |
| Friedreich ataxia | Typical sensory peripheral neuropathy in a patient diagnosed with Friedreich ataxia |
| Alcohol neuropathy | Typical sensory neuropathy in patients who consume alcohol. Patients describe painful (burning) sensations in limbs |
| Paraneoplastic | Subacute peripheral neuropathy in patients with neoplasm. The neuropathy could be the initial complaint for which the workup reveals the neoplasm. Positivity of onconeuronal antibodies, the finding of a tumor, and recuperation after removal of tumor align with the diagnosis |
| Critical illness polyneuropathy | Polyneuropathy in patients with prolonged stay in intensive care unit. Typically, patients would have received neurotropic drugs such as curare. Workup is usually unremarkable or could reveal metabolic anomalies |
| Chronic polyradiculoneuropathy | A Guillain–Barré-type presentation with chronic onset. Patients report tingling in extremities and then motor impairment in a length-dependent fashion |
| Deficiency neuropathy | Peripheral neuropathy in the context of vitamin deficiency. Patients present marked sensory signs with tingling and loss of proprioception. Vitamin B 12 deficiency might be associated with upper motor impairment (subacute combined degeneration of spinal cord) |
| Amyloid | Peripheral neuropathy in the context of amyloidosis, primary or secondary. Biopsy is required to show infiltration by the abnormal protein |
| Toxic | Peripheral neuropathy in a patient with known exposure to a toxin with potential to cause neuropathy. After excluding other etiologies, toxic neuropathy is retained. Patients are typically workers in manufacturing plants, painters, farmers, to name a few. Patients may also be drug-addicts (example: paint-thinner sniffers) |
Fig. 1Algorithm for paraclinical investigations in patients with peripheral neuropathies. ANA antinuclear antibody, CRP c-reactive protein, CSF cerebrospinal fluid, CT computed tomography, DNA deoxyribonucleic acid, EPP electrophoresis of proteins, EMG electromyography, ESR erythrocyte sedimentation rate, MRI magnetic resonance imaging, NCS nerve conduction studies, SSA Sjogren syndrome-A, SSB Sjogren syndrome-B
Fig. 2Distribution of cases per age of patient
Distribution of symptoms prompting consultation by patient
| Patient complaints | Frequency (%) | ||
|---|---|---|---|
Motor signs 86.6% | Weakness | 23 | 12.7 |
| Crampes/ fasciculations | 73 | 40.5 | |
| Peronial atrophy | 85 | 47.2 | |
Sensory signs 50.5% | Paresthesias | 60 | 33.3 |
| Dysesthesias | 16 | 8.9 | |
| Hypesthesia | 24 | 13.3 | |
| Pain | 19 | 10.5 | |
| Equilibrium problems | 10 | 5.5 | |
Neurovegetative signs 38.4% | Malaise (post prandial, orthostatic) | 42 | 23.3 |
| Sweat problems | 2 | 1.1 | |
| Problems with micturition | 35 | 19.4 | |
| Sexual disorders (erection, ejaculation) | 0 | 0 | |
| Motility diarrhea | 19 | 10.5 | |
| Trophic disorders | 2 | 1.1 |
Distribution of lab workup and neuroimaging
| Ordered | Normality status | ||||
|---|---|---|---|---|---|
| Not ordered | Ordered | Normal | Not normal | ||
| Hemogramme | 8 | 172 | 120 | 52 | |
| Renal function | 21 | 159 | 149 | 10 | |
| Hepatic function | 53 | 127 | 118 | 9 | |
| Hepatitis serology | 174 | 6 | 6 | 0 | |
| CRP | 25 | 155 | 142 | 13 | |
| ESR | 30 | 150 | 117 | 33 | |
| Glycemia | 18 | 162 | 92 | 70 | |
| Electrolytes | 87 | 93 | 84 | 9 | |
| CSF | 54 | 126 | 79 | 47 | |
| EPP CSF | 102 | 58 | 10 | 48 | |
| Thyroid function | 170 | 10 | 10 | 0 | |
| VDRL | 26 | 154 | 148 | 6 | |
| TPHA | 26 | 154 | 147 | 7 | |
| HIV | 70 | 110 | 108 | 2 | |
| EPP blood | 102 | 58 | 10 | 48 | |
| Lipid assay | 88 | 92 | 66 | 26 | |
| Borrelia serology | 169 | 11 | 11 | 0 | |
| Vitamin assay | Vit B12 | 170 | 10 | 8 | 2 |
| Vit E | 172 | 8 | 8 | 0 | |
| Immunological assay | Anti SSA (Ro), SSB (La) | 165 | 15 | 9 | 6 |
| Anti DNA | 167 | 13 | 13 | 0 | |
| Latex/ Waler Ross | 166 | 14 | 12 | 2 | |
| ANA | 170 | 10 | 10 | 0 | |
| Salivary gland biopsy | 160 | 20 | 5 | 15 | |
| CPK–LDH | 165 | 15 | 10 | 5 | |
| Koch bacillus | 161 | 19 | 18 | 1 | |
| Porphyrine dosing | 179 | 1 | 0 | 1 | |
| Nerve biopsy | 176 | 4 | 0 | 4 | |
| Neuroimaging | CT scan | 160 | 20 | 13 | 7 |
| MRI | 154 | 26 | 16 | 10 | |
Fig. 3Electrophysiological distribution of motor, sensory, sensorimotor and autonomic peripheral neuropathies
Comparison of etiologies of peripheral neuropathies with four other studies
| Our cohort ( | Egypt [ | Norway [ | Netherlands [ | Meta-analysis [ | |
|---|---|---|---|---|---|
| Diabetes | 26.7% | 20.40% | 18% | 32% | 34% |
| Inflammatory | 27.2% | 0.74% | 16%a | 9%c | 13%c |
| APRN | 26.1% | 0.37% | 12% | – | – |
| CPRN | 1.1% | 0.37% | 4% | – | – |
| ALS | 16.1% | – | – | – | – |
| Immunological disease | 5.6% | – | 4% | 5% | 4% |
| Idiopathic | 5% | 2.90% | 28% | 26% | 23% |
| Medication | 5%f | – | – | – | – |
| Infectious | 3.9% | 0.74% | 2% | – | – |
| Hereditary | – | 0.37%b | 14%b | 5% | 6% |
| Friedreich’s disease | 2.8% | 0.22% | – | – | – |
| Alcohol | 2.2% | – | 10% | – | – |
| Paraneoplastic | 1.7% | 0.07% | 3% | – | – |
| Critical illness polyneuropathy | 1.7% | – | – | – | – |
| Deficiency neuropathy | 1.1% | – | 4% | 4% | 3% |
| Amyloid | 0.6% | – | – | – | – |
| Toxic | 0.6% | – | – | 14%d | 13%d |
| Metabolic | – | 21.89%e | – | 4%e | 4%e |
| Hypoythroidism | – | 0.37% | 4% | – | – |
| Liver disease | – | 0.45% | 1% | – | – |
aInflammatory neuropathy = APRN, CPRN
bHereditary causes such as Charcot-Marie-Tooth were not found in our study; for reference 9, figure represents only Charcot-Marie-Tooth
cChronic inflammatory demyelinating polyneuropathy, Guillain–Barré syndrome, polyneuropathy associated with monoclonal gammopathy of undetermined significance, polyneuropathy associated with malignancy/neuronal paraneoplastic antibodies, and HIV, Lyme disease, leprosy-associated polyneuropathy
dVasculitic neuropathy, amyloid neuropathy, sarcoid neuropathy, and polyneuropathy with connective tissue disease, such as Sjögren disease and rheumatoid arthritis
eUremic polyneuropathy and neuropathy related to thyroid dysfunction, renal failure, and liver disease
fMedication-induced neuropathy in our study was due to cisplatine in 5 patients and isoniazide in 4 patients